Introduction: For primary cutaneous diffuse large B-cell lymphoma, leg-type (PC DLBCL-LT) there are no uniform recommendations for second-line treatment in case of relapse. Case presentation: Here we present the case of an elderly relapsed/refractory PC DLBCL-LT patient who obtained a prolonged clinical complete remission with lenalidomide. Conclusion: Lenalidomide as single agent led to an unexpected long complete response with manageable toxicity.
Prolonged Complete Response with Lenalidomide in a Relapsed Diffuse Large B-cell Lymphoma, Leg-type: A Case Report / Zoli, Sabrina; Pellegrini, Cinzia; Casadei, Beatrice; Broccoli, Alessandro; Argnani, Lisa; Nanni, Laura; Stefoni, Vittorio; Zinzani, Pier Luigi. - In: CHEMOTHERAPY. - ISSN 1421-9794. - ELETTRONICO. - 1:(2023), pp. 23-26. [10.1159/000534784]
Prolonged Complete Response with Lenalidomide in a Relapsed Diffuse Large B-cell Lymphoma, Leg-type: A Case Report
Zoli, Sabrina;Pellegrini, Cinzia;Casadei, Beatrice;Broccoli, Alessandro;Argnani, Lisa;Nanni, Laura;Stefoni, Vittorio;Zinzani, Pier Luigi
2023
Abstract
Introduction: For primary cutaneous diffuse large B-cell lymphoma, leg-type (PC DLBCL-LT) there are no uniform recommendations for second-line treatment in case of relapse. Case presentation: Here we present the case of an elderly relapsed/refractory PC DLBCL-LT patient who obtained a prolonged clinical complete remission with lenalidomide. Conclusion: Lenalidomide as single agent led to an unexpected long complete response with manageable toxicity.| File | Dimensione | Formato | |
|---|---|---|---|
|
Zoli_2023.pdf
accesso aperto
Tipo:
Versione (PDF) editoriale
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale (CCBYNC)
Dimensione
375.12 kB
Formato
Adobe PDF
|
375.12 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
